The influence of natural pulmonary surfactant on the efficacy of siRNA-loaded dextran nanogels

Nanomedicine

Volumn 8, Issue 10, 2013, Pages 1625-1638

  De Backer, Lynn ^a   Braeckmans, Kevin ^a   Demeester, Jo ^a   De Smedt, Stefaan C ^a   Raemdonck, Koen ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

Curosurf ; dextran nanogel; Infasurf ; lipoplex; polymeric nanoparticle; pulmonary surfactant; siRNA delivery

Indexed keywords

DEXTRAN; LIPOFECTAMINE; LUNG SURFACTANT; SMALL INTERFERING RNA;

ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FLOW CYTOMETRY; GENE SILENCING; IN VITRO STUDY; INTERNALIZATION; PRIORITY JOURNAL; RNA INTERFERENCE;

ADMINISTRATION, TOPICAL; ANIMALS; CELL LINE; DEXTRANS; DRUG DELIVERY SYSTEMS; GENETIC THERAPY; HUMANS; LUNG DISEASES; NANOPARTICLES; POLYETHYLENE GLYCOLS; POLYETHYLENEIMINE; PULMONARY SURFACTANTS; RNA, SMALL INTERFERING;

EID: 84885088332     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.203     Document Type: Article

References (38)

1. Raemdonck K, Vandenbroucke RE, Demeester J, Sanders NN, De Smedt SC. Maintaining the silence: Reflections on long-term RNAi. Drug Discov. Today 13(21-22), 917-931 (2008).
2. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: Advances in siRNA delivery. Nat. Rev. Drug Discov. 8(2), 129-138 (2009).
3. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat. Rev. Genet. 8(3), 173-184 (2007).
4. Pecot CV, Calin GA, Coleman RL, Lopez Berestein G, Sood AK. RNA interference in the clinic: Challenges and future directions. Nat. Rev. Cancer 11(1), 59-67 (2011).
5. Davidson BL, Mccray PB Jr. Current prospects for RNA interference-based therapies. Nat. Rev. Genet. 12(5), 329-340 (2011).
6. Lam JK, Liang W, Chan HK. Pulmonary delivery of therapeutic siRNA. Adv. Drug Deliv. Rev. 64(1), 1-15 (2011).
7. Merkel OM, Kissel T. Nonviral pulmonary delivery of siRNA. Acc. Chem. Res. 45, 961-970 (2012).
8. Merkel OM, Zheng M, Debus H, Kissel T. Pulmonary gene delivery using polymeric nonviral vectors. Bioconjug. Chem. 23, 3-20 (2012).
9. Sanders N, Rudolph C, Braeckmans K, De Smedt SC, Demeester J. Extracellular barriers in respiratory gene therapy. Adv. Drug Deliv. Rev. 61(2), 115-127 (2009).
10. Weiss DJ. Delivery of gene transfer vectors to lung: Obstacles and the role of adjunct techniques for airway administration. Mol. Ther. 6(2), 148-152 (2002).
11. Blanco O, Perez-Gil J. Biochemical and pharmacological differences between preparations of exogenous natural surfactant used to treat respiratory distress syndrome: Role of the different components in an efficient pulmonary surfactant. Eur. J. Pharmacol. 568(1-3), 1-15 (2007).
12. Haagsman HP, Hogenkamp A, Van Eijk M, Veldhuizen EJ. Surfactant collectins and innate immunity. Neonatology 93(4), 288-294 (2008).
13. Almlen A, Stichtenoth G, Linderholm B et al. Surfactant proteins B and C are both necessary for alveolar stability at end expiration in premature rabbits with respiratory distress syndrome. J. Appl. Physiol. 104(4), 1101-1108 (2008).
14. Duncan JE, Whitsett JA, Horowitz AD. Pulmonary surfactant inhibits cationic liposome-mediated gene delivery to respiratory epithelial cells in vitro. Hum. Gene Ther. 8(4), 431-438 (1997).
15. Ernst N, Ulrichskotter S, Schmalix WA et al. Interaction of liposomal and polycationic transfection complexes with pulmonary surfactant. J. Gene Med. 1(5), 331-340 (1999).
16. Rudolph C, Lausier J, Naundorf S, Muller RH, Rosenecker J. In vivo gene delivery to the lung using polyethylenimine and fractured polyamidoamine dendrimers. J. Gene Med. 2(4), 269-278 (2000).
17. Raemdonck K, Naeye B, Buyens K et al. Biodegradable dextran nanogels for RNA interference: Focusing on endosomal escape and intracellular siRNA delivery. Adv. Funct. Mater. 19(9), 1406-1415 (2009).
18. De Smedt SC, Van Thienen TG, Lucas B, Flesch FM, Van Nostrum CF, Demeester J. On the synthesis and characterization of biodegradable dextran nanogels with tunable degradation properties. Macromolecules 38(20), 8503-8511 (2005).
19. Vandijkwolthuis WNE, Tsang SKY, Kettenesvandenbosch JJ, Hennink WE. A new class of polymerizable dextrans with hydrolyzable groups: Hydroxyethyl methacrylated dextran with and without oligolactate spacer. Polymer 38(25), 6235-6242 (1997).
20. Zuo YY, Veldhuizen RA, Neumann AW, Petersen NO, Possmayer F. Current perspectives in pulmonary surfactant - inhibition, enhancement and evaluation. Biochim. Biophys. Acta 1778(10), 1947-1977 (2008).
21. Zhang H, Fan Q, Wang YE, Neal CR, Zuo YY. Comparative study of clinical pulmonary surfactants using atomic force microscopy. Biochim. Biophys. Acta 1808(7), 1832-1842 (2011).
22. Lucas B, Remaut K, Braeckmans K, Haustraete J, De Smedt SC, Demeester J. Studying pegylated DNA complexes by dual color fluorescence fluctuation spectroscopy. Macromolecules 37(10), 3832-3840 (2004).
23. Buyens K, Lucas B, Raemdonck K et al. A fast and sensitive method for measuring the integrity of siRNA-carrier complexes in full human serum. J. Control. Release 126(1), 67-76 (2008).
24. Payne CK, Jones SA, Chen C, Zhuang X. Internalization and trafficking of cell surface proteoglycans and proteoglycan-binding ligands. Traffic 8(4), 389-401 (2007).
25. Carralot JP, Kim TK, Lenseigne B et al. Automated high-throughput siRNA transfection in raw 264.7 macrophages: A case study for optimization procedure. J. Biomol. Screen. 14(2), 151-160 (2009).
26. Tseng YC, Mozumdar S, Huang L. Lipid-based systemic delivery of siRNA. Adv. Drug Deliv. Rev. 61(9), 721-731 (2009).
27. Moschos SA, Frick M, Taylor B et al. Uptake, efficacy and systemic distribution of naked, inhaled siRNA and locked nucleic acid (LNA) antisense. Mol. Ther. 19(12), 2163-2168 (2011).
28. Caldorera-Moore M, Guimard N, Shi L, Roy K. Designer nanoparticles: Incorporating size, shape and triggered release into nanoscale drug carriers. Expert Opin. Drug Deliv. 7(4), 479-495 (2010).
29. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem. J. 377(Pt 1), 159-169 (2004).
30. Steele TW, Zhao X, Tarcha P, Kissel T. Factors influencing polycation/siRNA colloidal stability toward aerosol lung delivery. Eur. J. Pharm. Biopharm. 80(1), 14-24 (2011).
31. Nguyen J, Reul R, Betz T et al. Nanocomposites of lung surfactant and biodegradable cationic nanoparticles improve transfection efficiency to lung cells. J. Control. Release 140(1), 47-54 (2009).
32. Benfer M, Kissel T. Cellular uptake mechanism and knockdown activity of siRNA-loaded biodegradable DEAPA-PVA-g-PLGA nanoparticles. Eur. J. Pharm. Biopharm. 80(2), 247-256 (2011).
33. Ruge CA, Kirch J, Canadas O et al. Uptake of nanoparticles by alveolar macrophages is triggered by surfactant protein A Nanomedicine 7(6), 690-693 (2011).
34. Bates SR. P63 (CKAP4) as an SP-A receptor: Implications for surfactant turnover. Cell. Physiol. Biochem. 25(1), 41-54 (2010).
35. Griese M. Pulmonary surfactant in health and human lung diseases: State of the art. Eur. Respir. J. 13(6), 1455-1476 (1999).
36. Frerking I, Gunther A, Seeger W, Pison U. Pulmonary surfactant: Functions, abnormalities and therapeutic options. Intensive Care Med. 27(11), 1699-1717 (2001).
37. Engle WA. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics 121(2), 419-432 (2008).
38. Maruscak A, Lewis JF. Exogenous surfactant therapy for ARDS. Expert Opin. Investig. Drugs 15(1), 47-58 (2006).